Ireland-based Tibotec, which is the subsidiary of Johnson & Johnson, has signed a royalty-free, non-exclusive license agreement with India’s Emcure Pharmaceuticals to distribute the protease inhibitor darunavir (DRV) in India.

Tibotec is ensuring access to innovative HIV/AIDS therapies and is said to have collaborated with Emcure because of the company's strong reputation in India and extensive reach through its countrywide distribution network. The agreement will help to build a sustainable effort in India to ensure patients have access to darunavir.

“We believe that strong collaborations with companies such as Emcure provide the best options for HIV/AIDS patients by enhancing drug access and maintaining the quality of medicines,” said Mr Wlodek Kubiak, VP (Worldwide Access Programs), Tibotec.

Tibotec is working with regulatory authorities in India to register darunavir. When approved, darunavir, co-administered with ritonavir and with other antiretroviral agents, may be indicated for the treatment of human immunodeficiency virus (HIV) infection in antiretroviral treatment.

“Emcure seeks to work with leaders in innovative new therapies such as Tibotec to provide important treatments for HIV for the Indian people,” said Mr Satish Mehta, CEO, Emcure. Darunavir is currently registered in 79 countries worldwide.